H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Verona Pharma (VRNA) to $60 from $42 and keeps a Buy rating on the shares following the “massive” Q4 revenue beat. Verona has been assigned a unique J-code for Ohtuvayre, J7601, which took effect at the beginning of this month, the analyst tells investors in a research note. The firm believes this should further facilitate market uptake.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRNA:
- Verona Pharma initiated with a Buy at Roth MKM
- Verona Pharma price target raised to $57 from $44 at Truist
- Verona Pharma price target raised to $74 from $64 at Wells Fargo
- Verona Pharma price target raised to $77 from $51 at BTIG
- Verona Pharma sees Q4 net product sales revenue $36M vs. $0M a year ago